Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 360 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subcutaneous Injection Clear all
Completed No phase listed Observational

Plegridy Observational Program

NCT02230969
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
50
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

NCT01628640
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00292396
View directory record Official record
Conditions
Psoriasis
Interventions
Anti IL-12 monoclonal antibody/ABT-874, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jul 23, 2026, 1:29 AM EDT
Completed No phase listed Observational

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

NCT01104142
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

NCT00071396
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Campath-1H, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Subcutaneous Injection in Healthy Participants

NCT06516913
View directory record Official record
Conditions
Healthy
Interventions
Harvard Apparatus syringe pump
Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
22 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

NCT00192517
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-522, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
18
States / cities
Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

NCT02833389
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcers
Interventions
Placebo, UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

NCT02805790
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 23, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 23, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

NCT03323749
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
elamipretide, placebo comparator, elamipretide open label treatment
Combination Product
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 23, 2026, 1:29 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

NCT04809376
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
Drug
Lead sponsor
Paradigm Biopharmaceuticals USA (INC)
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

NCT00033943
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
deligoparin
Drug
Lead sponsor
Incara Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
33
States / cities
Anaheim, California • Orange, California • Lakewood, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

NCT00048048
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

NCT04897412
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, Placebo
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jul 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults

NCT04408963
View directory record Official record
Conditions
HIV
Interventions
VRC-HIVMAB0102-00-AB
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 23, 2026, 1:29 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

NCT04143659
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
levonorgestrel butanoate (LB) injection
Biological
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
7
States / cities
Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 23, 2026, 1:29 AM EDT